MOLOGEN AG
MOLOGEN AG: Report of loss pursuant to section 92 para 1 of the German Stock Corporation Act
DGAP-News: MOLOGEN AG / Key word(s): Preliminary Results/Legal Matter Ad-hoc notification according to § 15 WpHG MOLOGEN AG: Report of loss pursuant to section 92 para 1 of the German Stock Corporation Act Berlin, July 11, 2016. Pursuant to Section 92 Para. 1 of the German Stock Corporation Act (AktG), the Executive Management Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) indicates that the Company’s provisional registered share capital is down to just EUR10,681,859.09 as of June 30, 2016 dated July 11, 2016 as a result of losses incurred. This means that half the Company’s share capital of EUR22,631,501.00 has been wiped out by losses. The losses mostly result from the Company’s ordinary activities as a research-based biotechnology company which is still developing and without revenues of its own. In the invitation to the Annual General Meeting which takes place on August 11, published on July 5, 2016 in the German Federal Gazette (Bundesanzeiger), the Executive Management Board has already announced under item 2 of the Agenda that a loss amounting to half the Company’s share capital was likely by the day of the Annual General Meeting at the latest. The Executive Management Board will indeed report an actual loss amounting to half the share capital at the Annual General Meeting and discuss this together with a funding proposal. The Company’s unaudited interim results to June 30, 2016 will be submitted to the Annual General Meeting. They will also be made available on the Company’s website at http://www.mologen.com/en/investor-relations-press/annual-general-meeting.html and will also be made available for shareholder inspection at the Annual General Meeting. – End of the ad-hoc notification – DISCLAIMER This announcement does not constitute an offer to buy shares or other securities of MOLOGEN AG and does not replace the prospectus. Investment decisions with respect to the shares or other securities of MOLOGEN AG shall only take place on the basis of the prospectus which will be available after the approval by the German Financial Supervisory Authority (BaFin) free of charge at MOLOGEN AG. Contact Note about risk for future predictions
2016-07-11 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |